Bacteriostatische en bactericide antibiotica

[Sproetje]

Uitleg waarom macroliden niet schadelijk zijn voor menselijke mitochodria:

https://biology.stackexchange.com/quest ... tochondria

[Sproetje]

Azitromycine gaat niet makkelijk in de rode bloedcellen
Hier een onderzoek van Pfizer:


http://aac.asm.org/content/40/1/75.full.pdf

The concentrations of azithromycin associated with erythrocytes were very much lower than those in both phagocytic cells and were even below the concentrations in plasma, suggesting only slight uptake by or association with erythrocytes

[Henriëtte]

Is Ceftriaxon adequate or enough?

From own experience, we are able to confirm the Klempner’s new study (from 2013). A mono-therapy (using only one substance) with ceftriaxon does not lead to any improvements or disappearing of the patient’s symptoms, not even in the long term. It is effective against the native spiral form of borrelias. But the therapy must also tackle persister forms of borrelias and from other pathogens, as well as co-infections and biofilms. This is the reason that the therapy should include a combination of antibiotics (see: Antibiotic Treatment, literature (1) and General Information, literature (2) and below). In the same way, even doxycycline as a mono-therapy may not be efficient enough.

The treatment with ceftriaxon should be reconsidered, since it does not attack persistent forms of borrelias or other pathogens, nor does it help against co-infections and biofilms (see: Antibiotic Treatment). A combination of distinct antibiotic substances must be employed in order to achieve this. These substances must have reduced risks and side effects, thus better metabolised by the body as the ones used currently (ceftriaxon and doxycycline). This way, we get a better risk/success relation during the therapy.

http://www.bca-clinic.de/our-opinion-st ... nfections/

Henriëtte